U.S. markets closed
  • S&P Futures

    3,829.50
    +20.25 (+0.53%)
     
  • Dow Futures

    31,027.00
    +115.00 (+0.37%)
     
  • Nasdaq Futures

    12,994.50
    +83.50 (+0.65%)
     
  • Russell 2000 Futures

    2,224.90
    +25.70 (+1.17%)
     
  • Crude Oil

    62.33
    +0.83 (+1.35%)
     
  • Gold

    1,735.10
    +6.30 (+0.36%)
     
  • Silver

    26.76
    +0.32 (+1.23%)
     
  • EUR/USD

    1.2092
    -0.0094 (-0.77%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • Vix

    27.95
    -0.94 (-3.25%)
     
  • GBP/USD

    1.3966
    -0.0047 (-0.33%)
     
  • USD/JPY

    106.4880
    +0.2580 (+0.24%)
     
  • BTC-USD

    45,540.76
    -1,014.98 (-2.18%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.29 (-3.99%)
     

Glenmark cuts price of COVID-19 drug favipiravir version to $1 per tablet

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
Tablets of Avigan (generic name : Favipiravir), a drug approved as an anti-influenza drug in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. are displayed during a photo opportunity in Tokyo
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

BENGALURU (Reuters) - Glenmark Pharmaceuticals Ltd said on Monday it would lower the price of its generic version of favipiravir, FabiFlu, to 75 rupees ($0.9983) per tablet for restricted emergency use in patients with mild-to-moderate COVID-19 symptoms in India.

Glenmark last month received Indian regulatory approval to make and sell anti-flu drug favipiravir, which is manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp.

Glenmark had priced FabiFlu at 103 rupees per tablet earlier, making it one of the cheapest COVID-19 treatment available in the country.

"Glenmark's price reduction aims to make FabiFlu further accessible for COVID-19 patients across the country," the company said in a statement https://reut.rs/3iZSbrJ.

The price reduction comes at a time when coronavirus cases are continuing to surge across India. The country registered a record increase in infections on Sunday, and has over 870,000 cases as of Monday, with the death toll at 23,174, according to federal health ministry data https://bit.ly/2VPOFGm.

Social media users have also complained of a shortage of COVID-19 treatment in the nation.

A treatment course with FabiFlu would require a patient to take 122 tablets over 14 days, and will now cost 8,475 rupees ($112.80) per patient at the new price.

Meanwhile, Japanese researchers on Friday said a clinical trial of Fujifilm's Avigan yielded inconclusive results as a treatment for COVID-19.

Dr.Reddy's Laboratories Ltd has entered into a deal with Fujifilm to sell Avigan globally excluding Japan, China and Russia.

Mumbai-based Glenmark has also commenced a post marketing surveillance study with FabiFlu to monitor its efficacy and safety in 1,000 patients that are prescribed with the oral antiviral, the company said.

($1 = 75.1300 Indian rupees)

(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Rashmi Aich)